CLINICAL_TRIALS
trial_result
· 2024-05-07
Clinical Trial Update: Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy [Phase 2]
Summary
Phase 2 trial evaluating OC-01 Nasal Spray in Neurotrophic Keratopathy has completed, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Oyster Point Pharma, Inc. | Conditions: Neurotrophic Keratopathy | Phase 2 | Status: COMPLETED | Results posted: 2024-05-07